Bacteria, Antibiotics and Immunity
Antibiotics have revolutionized modern medicine but antibiotic resistance is an increasing threat to health. The National, and International action plans demonstrate the necessity to develop innovative research to stop the progression of resistance in community-acquired and care-related bacterial infections. Antibiotics are uniquely considered as direct antimicrobial agents but there are several pieces of evidence that host immunity contributes to the efficacy of the antibiotic treatment. Deciphering the nature of cellular and molecular immune effectors contributing to antibiotic activity will open avenues to innovative approaches to combat infections with multidrug-resistant bacteria.
The team will promote two main research axes :
- Development of an adjunct therapy in bacterial pneumonia.
- Identification of immune correlates of protection throughout the differentiation and function of myeloid cells during antibiotic treatment of infections.
- Coordination of the European project FAIR which aims at testing a first-in-man clinical study of an aerosoltherapy stimulating respiratory innate immune defenses.
- Collaborative project with Pr Jan-Willem Veening, EPFL, on the identification of virulence factors of pneumococcus.
Biologist PharmD-PhD, GHICL
Clinician MD, CHU Lille
Post-doctoral fellow, Inserm
PhD student, Inserm-Univ Lille
PhD student, PhD Health program iSite-Univ Lille
PhD student, ARS-Univ Lille
PhD student, Inserm-Univ Lille
Matarazzo L, Casilag F, Porte R, Wallet F, Cayet D, Faveeuw C, Carnoy C, Sirard JC. 2019.
Therapeutic Synergy Between Antibiotics and Pulmonary Toll-Like Receptor 5 Stimulation in Antibiotic-Sensitive or -Resistant Pneumonia.
Front Immunol. 9;10:723.
Beshara, R., Sencio, V., Soulard, D., Barthelemy, A., Fontaine, J., Pinteau, T., Deruyter, L., Ismail, M.B., Paget, C., Sirard, J.C., Trottein, F., Faveeuw, C. 2018.
Alteration of Flt3-Ligand-dependent de novo generation of conventional dendritic cells during influenza infection contributes to respiratory bacterial superinfection.
PLoS Pathog 14, e1007360
Porte, R., Fougeron, D., Munoz-Wolf, N., Tabareau, J., Georgel, A.F., Wallet, F., Paget, C., Trottein, F., Chabalgoity, J.A., Carnoy, C., Sirard, J.C. 2015.
A Toll-Like Receptor 5 Agonist Improves the Efficacy of Antibiotics in Treatment of Primary and Influenza Virus-Associated Pneumococcal Mouse Infections.
Antimicrob Agents Chemother 59, 6064
Van Maele, L., Fougeron, D., Janot, L., Didierlaurent, A., Cayet, D., Tabareau, J., Rumbo, M., Corvo-Chamaillard, S., Boulenouar, S., Jeffs, S., Vande Walle, L., Lamkanfi, M., Lemoine, Y., Erard, F., Hot, D., Hussell, T., Ryffel, B., Benecke, A.G., Sirard, J.C. 2014.
Airway structural cells regulate TLR5-mediated mucosal adjuvant activity.
Mucosal Immunol 7, 489
Van Maele, L., Carnoy, C., Cayet, D., Ivanov, S., Porte, R., Deruy, E., Chabalgoity, J.A., Renauld, J.C., Eberl, G., Benecke, A.G., Trottein, F., Faveeuw, C., Sirard, J.C. 2014.
Activation of Type 3 innate lymphoid cells and interleukin 22 secretion in the lungs during Streptococcus pneumoniae infection.
J Infect Dis 210, 493.